tiprankstipranks
Advertisement
Advertisement

HK:9887 Stock Latest News

Nanjing Leads Biolabs Advances Key Bispecific Antibody Into Phase II Expansion for Biliary Tract Cancer
Company AnnouncementsNanjing Leads Biolabs Advances Key Bispecific Antibody Into Phase II Expansion for Biliary Tract Cancer
3d ago
9887
Nanjing Leads Biolabs Showcases Next-Generation Cancer ADCs at 2026 AACR Meeting
PremiumCompany Announcements
Nanjing Leads Biolabs Showcases Next-Generation Cancer ADCs at 2026 AACR Meeting
11d ago
9887
Nanjing Leads Biolabs Reshapes Board With Non-Executive Director Change
PremiumCompany Announcements
Nanjing Leads Biolabs Reshapes Board With Non-Executive Director Change
15d ago
9887
Nanjing Leads Biolabs Sets Out Board Composition and Committee Roles
PremiumCompany Announcements
Nanjing Leads Biolabs Sets Out Board Composition and Committee Roles
15d ago
9887
Nanjing Leads Biolabs Advances Lead Cancer Therapy and Bolsters Pipeline in 2025
PremiumCompany Announcements
Nanjing Leads Biolabs Advances Lead Cancer Therapy and Bolsters Pipeline in 2025
15d ago
9887
Nanjing Leads Biolabs Sets March 2026 Board Meeting to Approve 2025 Results and Consider Dividend
PremiumCompany AnnouncementsNanjing Leads Biolabs Sets March 2026 Board Meeting to Approve 2025 Results and Consider Dividend
25d ago
9887
Nanjing Leads Biolabs Added to Hang Seng Composite Index and Stock Connect Southbound List
Premium
Company Announcements
Nanjing Leads Biolabs Added to Hang Seng Composite Index and Stock Connect Southbound List
1M ago
9887
Nanjing Leads Biolabs Starts Phase II Trial of Opamtistomig in First-Line Esophageal Cancer
Premium
Company Announcements
Nanjing Leads Biolabs Starts Phase II Trial of Opamtistomig in First-Line Esophageal Cancer
1M ago
9887
Nanjing Leads Biolabs Starts Phase Ib/II Trial of Opamtistomig in Aggressive Breast Cancer
PremiumCompany Announcements
Nanjing Leads Biolabs Starts Phase Ib/II Trial of Opamtistomig in Aggressive Breast Cancer
2M ago
9887
Nanjing Leads Biolabs Wins FDA Fast Track Status for Multiple Myeloma Drug LBL-034
PremiumCompany Announcements
Nanjing Leads Biolabs Wins FDA Fast Track Status for Multiple Myeloma Drug LBL-034
2M ago
9887
Nanjing Leads Biolabs Wins EU Orphan Drug Status for LBL-024 in Rare Neuroendocrine Cancer
PremiumCompany Announcements
Nanjing Leads Biolabs Wins EU Orphan Drug Status for LBL-024 in Rare Neuroendocrine Cancer
3M ago
9887
Nanjing Leads Biolabs’ Cancer Antibody LBL-024 Wins FDA Fast Track Status for EP-NEC
PremiumCompany Announcements
Nanjing Leads Biolabs’ Cancer Antibody LBL-024 Wins FDA Fast Track Status for EP-NEC
3M ago
9887
Nanjing Leads Biolabs Sets Up Audit Committee to Strengthen Corporate Governance
PremiumCompany AnnouncementsNanjing Leads Biolabs Sets Up Audit Committee to Strengthen Corporate Governance
3M ago
9887
Nanjing Leads Biolabs Sets Formal Rules for Board Remuneration Committee
Premium
Company Announcements
Nanjing Leads Biolabs Sets Formal Rules for Board Remuneration Committee
3M ago
9887
Nanjing Leads Biolabs Sets Up Nomination Committee to Tighten Governance and Board Selection
Premium
Company Announcements
Nanjing Leads Biolabs Sets Up Nomination Committee to Tighten Governance and Board Selection
3M ago
9887
Nanjing Leads Biolabs Doses First Patient in Phase Ib/II Trial of LBL-024 for Platinum-Resistant Ovarian Cancer
PremiumCompany Announcements
Nanjing Leads Biolabs Doses First Patient in Phase Ib/II Trial of LBL-024 for Platinum-Resistant Ovarian Cancer
4M ago
9887
Nanjing Leads Biolabs Doses First Subject in Phase I Trial of Autoimmune Drug LBL-047
PremiumCompany Announcements
Nanjing Leads Biolabs Doses First Subject in Phase I Trial of Autoimmune Drug LBL-047
4M ago
9887
Nanjing Leads Biolabs Streamlines Governance and Introduces H Share Award Scheme
PremiumCompany Announcements
Nanjing Leads Biolabs Streamlines Governance and Introduces H Share Award Scheme
4M ago
9887
Nanjing Leads Biolabs Announces H Share Full Circulation Initiative
PremiumCompany Announcements
Nanjing Leads Biolabs Announces H Share Full Circulation Initiative
4M ago
9887
Nanjing Leads Biolabs Showcases Promising LBL-034 Data at ASH Meeting
PremiumCompany AnnouncementsNanjing Leads Biolabs Showcases Promising LBL-034 Data at ASH Meeting
4M ago
9887
Nanjing Leads Biolabs’ LBL-047 Receives IND Approval, Partners with Dianthus Therapeutics
Premium
Company Announcements
Nanjing Leads Biolabs’ LBL-047 Receives IND Approval, Partners with Dianthus Therapeutics
4M ago
9887
Nanjing Leads Biolabs Announces Extraordinary General Meeting to Discuss Key Resolutions
Premium
Company Announcements
Nanjing Leads Biolabs Announces Extraordinary General Meeting to Discuss Key Resolutions
4M ago
9887

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >